Why Rare Disease Therapeutics Need Early Market Access Planning

When developing and bringing a therapeutic for a rare disease to market, sponsors should think with the end in mind and plan for payer requirements early in protocol design. The economic and clinical value evidence required by payers for market access differs from the clinical efficacy and safety evidence demanded by regulators. Securing approval but lacking market access results in unrealized revenue and, most importantly, patients left untreated. But how do we price and how do we gain access on the promise of long-term value when we don’t have the long-term data?

In this podcast, originally broadcast by The Conference Forum's PHARMA talkRADIO, Sangeeta Budhia, VP and Global Head, Pricing and Market Access, and Wyatt Gotbetter, Worldwide Head, Access Consulting, of Parexel discuss early market access planning, including inclusive data collection, payer models and the impact of new regulations and innovative trial design on data collection and ongoing evidence provision.


Return to Insights Center

Related Insights


New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023


China's Market Approval Policy and Medical Insurance Payment System for Rare Disease

Jul 21, 2022


Overview of China's Market Approval Policy Med Insurance Payment System

Apr 7, 2022


Insights from the 2022 R&D Innovation Survey

Feb 17, 2023


Are you using real-world evidence?

Feb 1, 2023


Innovative modeling method could speed patient access to critical IO therapies

Jan 4, 2023


U.S. price reforms 2022: How can drug manufacturers best prepare for the Inflation Reduction Act?

Aug 17, 2022


Rachel Smith joins Parexel as Executive Director and Head of the Rare Disease, Center of Excellence

Aug 10, 2022


Preparing for a new era in European Market Access

Jul 22, 2022


To establish market access, start with unmet need: Why patient insights are central to reimbursement strategy

Apr 10, 2024


Reimbursement framework for medical devices in India

Mar 7, 2023


Parexel names first Patient Ambassador

Jun 17, 2022